
INNT
US listing · $23.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 20, 2020 | Time not confirmed | — | -0.23 | — |
| Nov 7, 2019 | Time not confirmed | -0.14 | -0.26 | -85.7% |
| Aug 8, 2019 | Time not confirmed | -0.13 | -0.13 | 0.0% |
| May 10, 2019 | Time not confirmed | -0.12 | -0.16 | -33.3% |
| Mar 18, 2019 | Time not confirmed | -0.21 | -0.12 | +45.0% |
| Nov 13, 2018 | Time not confirmed | -0.21 | -0.03 | +85.7% |
| Aug 14, 2018 | Time not confirmed | -0.21 | -0.16 | +23.8% |
| May 15, 2018 | Time not confirmed | — | -0.76 | — |
| Mar 13, 2018 | Time not confirmed | — | -3.16 | — |
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in…